<DOC>
	<DOCNO>NCT02756364</DOCNO>
	<brief_summary>The primary purpose study compare progression free survival ( PFS ) participant treat combination fulvestrant plus daily MLN0128 fulvestrant plus weekly MLN0128 versus participant treat single-agent fulvestrant .</brief_summary>
	<brief_title>MLN0128 Combination With Fulvestrant Women With Advanced Metastatic Breast Cancer After Aromatase Inhibitor Therapy</brief_title>
	<detailed_description>The drug test study call MLN0128 . MLN0128 test treat postmenopausal woman advance metastatic estrogen receptor ( ER ) positive , human epidermal growth factor receptor-2 ( HER2 ) negative breast cancer progress aromatase inhibitor ( AI ) therapy . This study evaluate efficacy safety combination fulvestrant + daily MLN0128 fulvestrant + weekly MLN0128 compare fulvestrant alone . The study enroll approximately 153 patient . Participants randomly assign ( chance , like flip coin ) one three treatment groups—which remain undisclosed participant study doctor study ( unless urgent medical need ) : - Fulvestrant 500 mg - Fulvestrant 500 mg + MLN0128 4 mg - Fulvestrant 500 mg + MLN0128 30 mg All participant receive either fulvestrant 500 mg intramuscularly ( IM ) , fulvestrant 500 mg + MLN0128 4 mg daily fulvestrant 500 mg + MLN0128 30 mg weekly . This multicenter trial conduct worldwide . Participants make multiple visit clinic , end treatment ( EOT ) visit occur 30 40 day receive last dose study drug start subsequent anticancer therapy . After EOT , participant follow progression free survival ( PFS ) overall survival ( OS ) .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Aromatase Inhibitors</mesh_term>
	<mesh_term>Fulvestrant</mesh_term>
	<mesh_term>Estradiol</mesh_term>
	<criteria>1 . Female participant age 18 year old postmenopausal . 2 . Histologically proven diagnosis breast cancer evidence metastatic disease locoregional recurrence . 3 . Histological confirmation documentation estrogen receptor ( ER ) positive status ( ≥1 % positive stained cell ) . 4 . Histological cytological confirmation documentation human epidermal growth factor receptor2 ( HER2 ) negative status local laboratory test use criterion American Society Oncology ( ASCO ) /College American Pathologists ( CAP ) Clinical Practice Guideline update . 3 . Measureable disease 4 . Progressive Disease ( PD ) prior aromatase inhibitor ( AI ) therapy . 5 . Have history brain metastasis provide follow criterion meet : Brain metastasis treat . No evidence PD ≥3 month first dose study drug . No hemorrhage treatment . Off dexamethasone treatment ≥4 week first dose study drug . No ongoing requirement dexamethasone antiepileptic drug . 6 . Eastern cooperative oncology group ( ECOG ) performance status 0 1 . 7 . Clinical laboratory value specify within 4 week first dose study drug : Bone marrow reserve consistent absolute neutrophil count ( ANC ) ≥1.5*10^9/L ; platelet count ≥100*10^9/L ; hemoglobin ( Hgb ) ≥9 g/dL . Total bilirubin ≤1.5*the upper limit normal range ( ULN ) , aspartate aminotransferase ( AST ) alanine aminotransferase ( ALT ) ≤2.5*ULN ( ≤5*ULN liver metastasis present ) . Creatinine clearance ≥40 mL/min base CockcroftGault estimate base 12 24hour urine collection . Fasting serum glucose ≤130 mg/dL fast triglyceride ≤300 mg/dL . 1 . Prior therapy mechanistic target rapamycin ( mTOR ) , phosphoinositide3kinase ( PI3K ) , dual PI3KmTOR inhibitor , serine/threoninespecific protein kinase ( AKT ) inhibitor , fulvestrant . 2 . Prior treatment &gt; 1 line chemotherapy metastatic breast cancer locoregional recurrence amenable resection radiation therapy curative intent . 3 . Experienced recurrent PD &gt; 2 endocrine therapy metastatic breast cancer locoregional recurrence amenable resection radiation therapy curative intent . 4 . Lifethreatening metastatic visceral disease ( defined extensive hepatic involvement symptomatic pulmonary lymphangitic spread ) . 5 . Poorly control diabetes mellitus define hemoglobin A1c ( glycosylated hemoglobin ; HbA1c ) &gt; 7 % ; participant history transient glucose intolerance due corticosteroid administration may eligible inclusion/exclusion criterion meet .</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2017</verification_date>
	<keyword>Drug Therapy</keyword>
</DOC>